查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2030 年神经调节市场预测：按类型、生物材料、技术、应用、最终用户和地区进行的全球分析
市场调查报告书
商品编码
1383435

2030 年神经调节市场预测：按类型、生物材料、技术、应用、最终用户和地区进行的全球分析

Neuromodulation Market Forecasts to 2030 - Global Analysis By Type, Biomaterial, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球神经调节市场规模将达到 68 亿美元，预计 2030 年将达到 168 亿美元，预测期内年复合成长率为 13.8%。

神经调节是一种医疗程序，涉及向神经系统特定区域提供电或化学刺激的植入设备。它用于治疗各种神经和精神疾病。许多神经调节方法是非侵入性或微创的，这意味着它们不涉及手术或主要的物理干预。这可以加快康復速度并降低与侵入性手术相关的风险。

根据美国疾病管制与预防美国(CDC) 的数据，中风是美国的首要死因，2019 年有 15 万美国死亡。

扩大神经调节疗法的接受度

神经调节治疗方法越来越多地被用作手术和阿片类药物等传统医学治疗的安全有效的替代方案。与传统治疗方法相比，这些治疗方法已被证明具有更少的副作用和更低的成瘾风险，同时可以长期缓解慢性疼痛等神经病变。此外，广泛的临床研究和临床试验已经确定了神经调节治疗的有效性和安全性。只要神经调节疗法被认为是一种安全有效的治疗方法，特别是随着神经系统疾病的盛行率不断增加，神经调节设备市场就有望扩大。随着神经调节治疗需求的增加，市场预计将扩大。

药物偏好

在神经系统疾病的治疗中，患者往往喜欢药物治疗而不是神经调节治疗。这是因为患者不知道可以使用基于神经调节装置的手术替代方案。在一些国家，外科医生也表现出这种意识的缺乏。由于缺乏对使用生物材料和神经调节设备治疗多种神经系统疾病的好处的认识，预计将在预测期内限制该市场的成长。

技术进步

技术开拓对神经调节领域产生重大影响，为市场扩张和进步提供了巨大潜力。迄今为止的发展导致设备日益复杂和高效，改善了患者的治疗效果并扩大了神经调节治疗的应用。更紧凑的植入式设备已被开发出来，以提高患者的舒适度并实现侵入性较小的手术。这些进展提高了患者的可接受性，扩大了神经调节治疗的范围，并降低了其侵入性程度。

高成本

这些设备和治疗方法的高成本经常被认为是其采用和使用的障碍，因为它会限制患者和提供者的使用。神经调节设备的开发和製造成本高昂，这些成本通常由病人、医院和保险公司承担。无力负担神经调节设备和治疗方法的患者可能无法接受它们，尤其是在医疗资源不足的国家。因此，高成本是市场拓展的主要障碍。

COVID-19 的影响

由于许多国家持续封锁，大多数医院都关闭，因此预计 COVID-19 大流行将阻碍神经调节市场的扩张。 COVID-19 大流行为公共卫生带来了严峻挑战。同时，世界各地的许多诊所和医院正在进行结构性改革，以提高医院容量并提供更好的医疗设施。

预计内部部门在预测期内将是最大的

由于患有心臟相关疾病、忧郁症和各种头痛的患者数量不断增加，预计内科所占比例最大。神经调节装置对于慢性疼痛的治疗至关重要，因为它们采用非侵入性或微创技术。内部神经调节是一种更有效的治疗方法，因为它是一种透过电刺激疼痛部位的特定神经来改变神经活动的装置。

在预测期内，年复合成长率最高的将是慢性疼痛领域。

预计慢性疼痛细分市场在预测期内将出现良好的成长。慢性疼痛管理有助于透过药物、治疗方法和生活方式改变来缓解疼痛。电刺激设备对疼痛管理有重大影响，因为它们最初设计用于缓解各种型态的急性和慢性疼痛。久坐的生活方式、高龄化和慢性病的流行是导致慢性疼痛的危险因子。因此，慢性疼痛发病率的增加预计将在预测期内推动该细分市场的成长。

比最大的地区

在预测期内，北美占据最大的市场占有率。庞大的製药和生物製药行业、成熟的市场参与企业以及美国为引进最尖端科技而增加的投资预计将推动该国市场的成长。此外，在过去的年度中，PD 在北美的发生率比多发性硬化症、肌肉萎缩症和卢伽雷氏症的总合还要多。因此，该国的研究人员正在详细研究神经调节来治疗这些神经系统疾病。这为尖端神经调节设备的开发开闢了新途径，预计将有助于该地区的整体市场成长。

复合年复合成长率最高的地区：

由于患者人数众多、医疗保健支出不断增加以及对神经调节疗法的认识不断增强，预计亚太地区在预测期内将实现盈利增长。该地区也投入大量资金用于神经调节疗法和设备的研发。由于患者人数众多且神经调节治疗的使用不断增加，中国和日本目前占据该地区的前两名。然而，该地区其他国家的市场也大幅扩张，例如澳洲、韩国、印度和韩国。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球神经调节市场：依类型

  • 介绍
  • 经皮神经电刺激
  • 呼吸电刺激
  • 经颅磁刺激
  • 脑深部刺激
  • 脊髓刺激
  • 荐椎神经刺激
  • 迷走神经刺激
  • 胃电刺激

第6章全球神经调节市场：依生物材料分类

  • 介绍
  • 金属生物材料
  • 高分子生物材料
  • 陶瓷生物材料

第7章全球神经调节市场：依技术分类

  • 介绍
  • 外部的
  • 内部的

第8章全球神经调节市场：依应用分类

  • 介绍
  • 偏头痛
  • 帕金森氏症
  • 尿失禁和大便失禁
  • 慢性疼痛
  • 故障恢復症候群
  • 发抖
  • 癫痫
  • 忧郁症
  • 其他用途

第9章全球神经调节市场：依最终用户分类

  • 介绍
  • 诊所和物理治疗中心
  • 医院及门诊手术中心

第10章全球神经调节市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第11章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第12章公司简介

  • Nevro Corporation
  • NeuroSigma
  • Bioventus Inc.
  • Medtronic
  • NeuroPace Inc
  • Neuronetics
  • Boston Scientific Corporation
  • LivaNova PLC
  • MicroTransponder
  • Abbott
  • Synapse Biomedical Inc
  • Nuvectra
  • Soterix Medical
Product Code: SMRC24284

According to Stratistics MRC, the Global Neuromodulation Market is accounted for $6.8 billion in 2023 and is expected to reach $16.8 billion by 2030 growing at a CAGR of 13.8% during the forecast period. Neuromodulation is a medical procedure involving implanted devices to deliver electrical or chemical stimulation to specific areas of the nervous system. It is used to treat a variety of neurological and psychiatric conditions. Numerous neuromodulation methods don't involve surgery or significant physical intervention because they are non-invasive or minimally invasive. This enables quicker recovery times and lowers the risks related to invasive procedures.

According to Centers for Disease Control and Prevention (CDC), stroke is a leading cause of death in the U.S., killing 150,000 Americans in 2019.

Market Dynamics:

Driver:

Rising acceptance of neuromodulation therapies

The use of neuromodulation therapies as secure and efficient substitutes for conventional medical procedures like surgery and opioids is growing. Compared to conventional treatments, these therapies have been demonstrated to have fewer side effects and a lower risk of addiction while providing long-term relief for neurological disorders such as chronic pain. Furthermore, an abundance of clinical research and trials have substantiated the efficacy and safety of neuromodulation treatments. The market for neuromodulation devices is anticipated to rise as long as neuromodulation therapies are acknowledged as safe and effective forms of treatment, particularly in light of the rising incidence of neurological disorders. The market is expected to grow as a result of the growing need for neuromodulation therapies.

Restraint:

Preference of drug therapies

While treating neurological disorders, patients frequently favor drug therapies over neuromodulation. This is because of patients' lack of knowledge regarding the availability of neuromodulation device-based alternative surgical treatments. In certain countries, surgeons also exhibit this lack of awareness. The lack of awareness about the benefits of using biomaterials or neuromodulation devices to treat several neurological disorders is expected to restrain the growth of this market during the forecast period.

Opportunity:

Technological advancements

Technological developments offer enormous potential for market expansion and advancement and have greatly impacted the field of neuromodulation. The development that has been made has led to the creation of increasingly complex and efficient devices, enhanced patient outcomes, and broadened the scope of uses for neuromodulation treatments. Devices that are more compact and implantable have been created, improving patient comfort and enabling less invasive procedures. These developments have improved patient acceptance, broadened the range of applications for neuromodulation therapies, and decreased the degree of invasiveness.

Threat:

High cost

The high cost of these devices and therapies is often cited as a barrier to their adoption and use, as it can limit access for patients and healthcare providers. Neuromodulation devices can be costly to develop and produce, and this expense is frequently borne by patients, hospitals, and insurance companies. Patients who cannot afford neuromodulation devices and therapies may not be able to receive them, particularly in nations with inadequate healthcare resources. Therefore, high cost is a significant barrier for the market expansion.

COVID-19 Impact

The COVID-19 pandemic is expected to hinder the neuromodulation market's expansion since most hospitals are closed as a result of the ongoing lockdowns in many nations. The COVID-19 pandemic has caused a serious problem for public health. On the other hand, a great number of clinics and hospitals around the world underwent structural changes to boost hospital capacity and offer better healthcare facilities.

The internal segment is expected to be the largest during the forecast period

The internal segment is estimated to hold the largest share, due to increase in the number of patients suffering from heart-related diseases, depression, and various headache disorders. Neuromodulation devices are vital in the treatment of chronic pain because they employ non-invasive or minimally invasive technology. Internal neuromodulation is a more effective way to treat the condition because the devices are made to electrically stimulate a specific nerve at the pain site in order to alter nerve activity.

The chronic pain segment is expected to have the highest CAGR during the forecast period

The chronic pain segment is anticipated to have lucrative growth during the forecast period. Chronic pain management helps relieve pain with the use of drugs, therapies, and lifestyle changes. Since electrical stimulation devices were initially designed to relieve various forms of acute and chronic pain, they have a significant impact on pain management. A sedentary lifestyle, an aging population, and the prevalence of chronic conditions are a few risk factors that could lead to chronic pain. Thus, during the projected period, the growing incidence of chronic pain is anticipated to propel the segment's growth.

Region with largest share:

North America commanded the largest market share during the extrapolated period. The large pharmaceutical and biopharmaceutical industries, along with the presence of well-established market players and growing investments in the United States for the adoption of cutting-edge technologies, are anticipated to drive the market's growth in this country. Furthermore, during the past decade, PD has become more common in North America than multiple sclerosis, muscular dystrophy, and Lou Gehrig's disease combined. Therefore, in order to treat these neurological disorders, the nation's researchers investigate neuromodulation in great detail. This is expected to create new avenues for the development of cutting-edge neuromodulation devices and contribute to the region's overall market growth.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period, due to the large patient population, increasing healthcare expenditure, and rising awareness about neuromodulation therapies. Considerable funds are also being invested in the region's research and development of neuromodulation therapies and devices. Because of their sizable patient populations and rising use of neuromodulation treatments, China and Japan presently hold the top two positions in the region. However, the market is expanding significantly in other nations in the region as well, including Australia, South Korea, India, and South Korea.

Key players in the market

Some of the key players in the Neuromodulation Market include: Nevro Corporation, NeuroSigma, Bioventus Inc., Medtronic, NeuroPace Inc, Neuronetic, Boston, Scientific Corporation, LivaNova PLC, MicroTransponder, Abbott, Synapse Biomedical Inc, Nuvectra and Soterix Medical.

Key Developments:

In February 2022, Medtronic (Ireland) received FDA approval for its InterStim X System, a next-generation personalized sacral nerve stimulation therapy for bladder and bowel control.

In June 2021, NeuroSigma (US) and KT Corporation (South Korea) signed a memorandum of understanding for a strategic partnership to develop and commercialize, inside and outside of Korea, electronic therapies treating neurological and neuropsychological disorders, including ADHD, depression, and epilepsy.

In January 2020, Medtronic Plc (Ireland) acquired Stimgenics, LLC (US), a privately held US-based company. This acquisition helped strengthen Medtronic's portfolio of spinal cord stimulation systems.

Types Covered:

  • Transcutaneous Electrical Nerve Stimulation
  • Respiratory Electrical Stimulation
  • Transcranial Magnetic Stimulation
  • Deep Brain Stimulation
  • Spinal Cord Stimulation
  • Sacral Nerve Stimulation
  • Vagus Nerve Stimulation
  • Gastric Electrical Stimulation

Biomaterials Covered:

  • Metallic Biomaterial
  • Polymeric Biomaterial
  • Ceramic Biomaterial

Technologies Covered:

  • External
  • Internal

Applications Covered:

  • Migraine
  • Parkinson Disease
  • Urinary And Fecal Incontinence
  • Chronic Pain
  • Failed Back Syndrome
  • Tremor
  • Epilepsy
  • Depression
  • Other Applications

End Users Covered:

  • Clinics & Physiotherapy Centers
  • Hospitals & Ambulatory Surgery Centers

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neuromodulation Market, By Type

  • 5.1 Introduction
  • 5.2 Transcutaneous Electrical Nerve Stimulation
  • 5.3 Respiratory Electrical Stimulation
  • 5.4 Transcranial Magnetic Stimulation
  • 5.5 Deep Brain Stimulation
  • 5.6 Spinal Cord Stimulation
  • 5.7 Sacral Nerve Stimulation
  • 5.8 Vagus Nerve Stimulation
  • 5.9 Gastric Electrical Stimulation

6 Global Neuromodulation Market, By Biomaterial

  • 6.1 Introduction
  • 6.2 Metallic Biomaterial
  • 6.3 Polymeric Biomaterial
  • 6.4 Ceramic Biomaterial

7 Global Neuromodulation Market, By Technology

  • 7.1 Introduction
  • 7.2 External
  • 7.3 Internal

8 Global Neuromodulation Market, By Application

  • 8.1 Introduction
  • 8.2 Migraine
  • 8.3 Parkinson Disease
  • 8.4 Urinary And Fecal Incontinence
  • 8.5 Chronic Pain
  • 8.6 Failed Back Syndrome
  • 8.7 Tremor
  • 8.8 Epilepsy
  • 8.9 Depression
  • 8.10 Other Applications

9 Global Neuromodulation Market, By End User

  • 9.1 Introduction
  • 9.2 Clinics & Physiotherapy Centers
  • 9.3 Hospitals & Ambulatory Surgery Centers

10 Global Neuromodulation Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Nevro Corporation
  • 12.2 NeuroSigma
  • 12.3 Bioventus Inc.
  • 12.4 Medtronic
  • 12.5 NeuroPace Inc
  • 12.6 Neuronetics
  • 12.7 Boston Scientific Corporation
  • 12.8 LivaNova PLC
  • 12.9 MicroTransponder
  • 12.10 Abbott
  • 12.11 Synapse Biomedical Inc
  • 12.12 Nuvectra
  • 12.13 Soterix Medical

List of Tables

  • Table 1 Global Neuromodulation Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Neuromodulation Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Neuromodulation Market Outlook, By Transcutaneous Electrical Nerve Stimulation (2021-2030) ($MN)
  • Table 4 Global Neuromodulation Market Outlook, By Respiratory Electrical Stimulation (2021-2030) ($MN)
  • Table 5 Global Neuromodulation Market Outlook, By Transcranial Magnetic Stimulation (2021-2030) ($MN)
  • Table 6 Global Neuromodulation Market Outlook, By Deep Brain Stimulation (2021-2030) ($MN)
  • Table 7 Global Neuromodulation Market Outlook, By Spinal Cord Stimulation (2021-2030) ($MN)
  • Table 8 Global Neuromodulation Market Outlook, By Sacral Nerve Stimulation (2021-2030) ($MN)
  • Table 9 Global Neuromodulation Market Outlook, By Vagus Nerve Stimulation (2021-2030) ($MN)
  • Table 10 Global Neuromodulation Market Outlook, By Gastric Electrical Stimulation (2021-2030) ($MN)
  • Table 11 Global Neuromodulation Market Outlook, By Biomaterial (2021-2030) ($MN)
  • Table 12 Global Neuromodulation Market Outlook, By Metallic Biomaterial (2021-2030) ($MN)
  • Table 13 Global Neuromodulation Market Outlook, By Polymeric Biomaterial (2021-2030) ($MN)
  • Table 14 Global Neuromodulation Market Outlook, By Ceramic Biomaterial (2021-2030) ($MN)
  • Table 15 Global Neuromodulation Market Outlook, By Technology (2021-2030) ($MN)
  • Table 16 Global Neuromodulation Market Outlook, By External (2021-2030) ($MN)
  • Table 17 Global Neuromodulation Market Outlook, By Internal (2021-2030) ($MN)
  • Table 18 Global Neuromodulation Market Outlook, By Application (2021-2030) ($MN)
  • Table 19 Global Neuromodulation Market Outlook, By Migraine (2021-2030) ($MN)
  • Table 20 Global Neuromodulation Market Outlook, By Parkinson Disease (2021-2030) ($MN)
  • Table 21 Global Neuromodulation Market Outlook, By Urinary And Fecal Incontinence (2021-2030) ($MN)
  • Table 22 Global Neuromodulation Market Outlook, By Chronic Pain (2021-2030) ($MN)
  • Table 23 Global Neuromodulation Market Outlook, By Failed Back Syndrome (2021-2030) ($MN)
  • Table 24 Global Neuromodulation Market Outlook, By Tremor (2021-2030) ($MN)
  • Table 25 Global Neuromodulation Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 26 Global Neuromodulation Market Outlook, By Depression (2021-2030) ($MN)
  • Table 27 Global Neuromodulation Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 28 Global Neuromodulation Market Outlook, By End User (2021-2030) ($MN)
  • Table 29 Global Neuromodulation Market Outlook, By Clinics & Physiotherapy Centers (2021-2030) ($MN)
  • Table 30 Global Neuromodulation Market Outlook, By Hospitals & Ambulatory Surgery Centers (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.